FDA Faces Succession Questions As Hahn’s Departure Nears
Executive Summary
Plan specifying the acting head of the US FDA until new commissioner is confirmed references senior positions that no longer exist.
You may also be interested in...
Woodcock To Be Acting US FDA Commissioner, Leaving Agency in Stable, Capable Hands
The agency has been prepping Woodcock for the temporary task but what will happen to her role on Operation Warp Speed remains unclear. The move should give the incoming Biden team cushion to confirm a permanent leader, of whom a top contender is former senior FDA staffer Joshua Sharfstein.
Gene Therapy: Pediatric Development Could Start Sooner Than Sponsors Think – FDA OTP Director
Nicole Verdun said children could participate in gene therapy clinical trials earlier if the necessary controls are in place.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.